[HTML][HTML] The signal pathways and treatment of cytokine storm in COVID-19
L Yang, X Xie, Z Tu, J Fu, D Xu, Y Zhou - Signal transduction and …, 2021 - nature.com
Abstract The Coronavirus Disease 2019 (COVID-19) pandemic has become a global crisis
and is more devastating than any other previous infectious disease. It has affected a …
and is more devastating than any other previous infectious disease. It has affected a …
[HTML][HTML] Cytokine storm
DC Fajgenbaum, CH June - New England Journal of Medicine, 2020 - Mass Medical Soc
Cytokine Storm Cytokine storm, a life-threatening disorder involving cytokine elevations and
immune-cell hyperactivation, has various causes and is characterized by constitutional …
immune-cell hyperactivation, has various causes and is characterized by constitutional …
[HTML][HTML] Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 …
Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …
Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review
L Ghosn, R Assi, T Evrenoglou… - Cochrane database …, 2023 - cochranelibrary.com
Background It has been reported that people with COVID‐19 and pre‐existing
autoantibodies against type I interferons are likely to develop an inflammatory cytokine storm …
autoantibodies against type I interferons are likely to develop an inflammatory cytokine storm …
Effect of canakinumab vs placebo on survival without invasive mechanical ventilation in patients hospitalized with severe COVID-19: a randomized clinical trial
Importance Effective treatments for patients with severe COVID-19 are needed. Objective To
evaluate the efficacy of canakinumab, an anti–interleukin-1β antibody, in patients …
evaluate the efficacy of canakinumab, an anti–interleukin-1β antibody, in patients …
[HTML][HTML] Calming the cytokine storm in COVID-19
RQ Cron, R Caricchio, WW Chatham - Nature medicine, 2021 - nature.com
Calming the cytokine storm in COVID-19 | Nature Medicine Skip to main content Thank you for
visiting nature.com. You are using a browser version with limited support for CSS. To obtain the …
visiting nature.com. You are using a browser version with limited support for CSS. To obtain the …
[HTML][HTML] Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis
Background Anakinra might improve the prognosis of patients with moderate to severe
COVID-19 (ie, patients requiring oxygen supplementation but not yet receiving organ …
COVID-19 (ie, patients requiring oxygen supplementation but not yet receiving organ …
[HTML][HTML] Evidence regarding vitamin D and risk of COVID-19 and its severity
J Mercola, WB Grant, CL Wagner - Nutrients, 2020 - mdpi.com
Vitamin D deficiency co-exists in patients with COVID-19. At this time, dark skin color,
increased age, the presence of pre-existing illnesses and vitamin D deficiency are features …
increased age, the presence of pre-existing illnesses and vitamin D deficiency are features …
[HTML][HTML] Interleukin-1 and the NLRP3 inflammasome in COVID-19: Pathogenetic and therapeutic implications
A hyperinflammatory response during severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infection crucially worsens clinical evolution of coronavirus disease 2019 …
(SARS-CoV-2) infection crucially worsens clinical evolution of coronavirus disease 2019 …
[HTML][HTML] Alterations in microbiota of patients with COVID-19: potential mechanisms and therapeutic interventions
The global coronavirus disease 2019 (COVID-19) pandemic is currently ongoing. It is
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A high …
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A high …